IRX4204 is an orally available second generation highly selective RXR agonist. It has shown activity against a variety of human cancers in vitro and in animal models, including prostate, breast, pancreas, and lung. Preclinical studies have also demonstrated potential for the drug to be active in Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.

A Phase I/II study of IRX4204 conducted at the USC medical center demonstrated IRX4204 was well tolerated through escalation of multiple doses. In this clinical trial, indications of possible anti-tumor activity were observed across a broad range of cancers.

A Phase II clinical trial of IRX4204 in prostate cancer is complete. The company plans to conduct clinical trials in Parkinson’s disease, and multiple sclerosis.